OSGIN2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10551(OSGIN2 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10551(OSGIN2 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

OSGIN2 (Oxidative Stress Induced Growth Inhibitor 2) is a protein encoded by the *OSGIN2* gene, belonging to a family of stress-responsive proteins implicated in cellular responses to oxidative stress, DNA damage, and apoptosis. It shares structural homology with its paralog OSGIN1 and is regulated by pathways involving p53 and NRF2. linking it to tumor suppression and antioxidant defense mechanisms. OSGIN2 is thought to modulate cell cycle arrest, apoptosis, and autophagy under stress conditions, though its precise molecular functions remain less characterized compared to OSGIN1.

Antibodies targeting OSGIN2 are essential tools for studying its expression, localization, and role in physiological and pathological processes. These antibodies are typically validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Research utilizing OSGIN2 antibodies has explored its involvement in diseases like cancer, neurodegenerative disorders, and metabolic syndromes, where oxidative stress and aberrant cell survival pathways are key drivers. For instance, OSGIN2 dysregulation has been observed in certain cancers, suggesting potential roles in tumorigenesis or chemoresistance.

Commercial OSGIN2 antibodies are often raised against specific epitopes, with validation data ensuring specificity toward human, mouse, or rat isoforms. Researchers prioritize antibodies with minimal cross-reactivity to related proteins (e.g., OSGIN1) to avoid misinterpretation. As interest in redox biology grows, OSGIN2 antibodies continue to support mechanistic studies of stress adaptation and therapeutic targeting in disease models.